Previous Article | Next Article ![]()
Infection and Immunity, November 2001, p. 6823-6830, Vol. 69, No. 11
Baxter Healthcare Corporation, Columbia,
Maryland 21046-2358
Received 11 April 2001/Returned for modification 22 May
2001/Accepted 7 August 2001
Pertussis toxin (Ptx) expression and secretion in Bordetella
pertussis are regulated by a two-component signal transduction system encoded by the bvg regulatory locus. However, it
is not known whether the metabolic pathways and growth state of the
bacterium influence synthesis and secretion of Ptx and other virulence
factors. We have observed a reduction in the concentration of Ptx per
optical density unit midway in fermentation. Studies were conducted to identify possible factors causing this reduction and to develop culture
conditions that optimize Ptx expression. Medium reconstitution experiments demonstrated that spent medium and a fraction of this medium containing components with a molecular weight of <3,000 inhibited the production of Ptx. A complete flux analysis of the intermediate metabolism of B. pertussis revealed that
the sulfur-containing amino acids methionine and cysteine and the
organic acid pyruvate accumulated in the media. In fermentation, a
large amount of internal sulfate (SO42 Bordetella pertussis is
the causative agent of whooping cough. The development and utilization
of vaccines against B. pertussis have greatly reduced the
morbidity and mortality caused by this pathogen throughout the world.
The toxicity associated with the whole-cell pertussis vaccines
(39) has led to the development of a new generation of
acellular vaccines containing one or more virulence factors (38,
41). Acellular vaccines that contain pertussis toxin (Ptx)
require isolation and purification of active toxin from the media of
batch fermentation (45). The number of doses per
fermentation volume of acellular vaccine is estimated to be fivefold
lower than that for a whole-cell vaccine (45). Therefore,
there has been much interest in improving product yields through medium
optimization, compound addition, and genetic manipulation of the
B. pertussis strains.
B. pertussis is routinely cultured in Stainer-Scholte (SS)
medium (46) or a modified derivative. These media contain
glutamate as the primary source of carbon, because B. pertussis has an incomplete citric acid cycle and is not capable
of using glucose. Growth in SS medium results in a final dry cell
weight of 2 g/liter and a Ptx concentration of 5 to 10 mg/liter
(51). During growth in these media, ammonium accumulates
because of an imbalance in the nitrogen/carbon ratio of the components,
which is one of the factors that limit cell density in fermentation and
decrease the growth rate (1). Increasing the amount of
glutamate in cultures has been shown to increase the final cell
density, but not the amount of Ptx (51). However,
adjusting the ionic composition of the media, maintaining pH at 7.0 (15), and growing cultures in pure oxygen have improved
the Ptx yield in cultures containing a higher glutamate concentration.
In addition, the presence of free fatty acids in the media has been
reported to be either inhibitory or stimulatory for growth
(13). Addition of
heptakis-(2,6-O-dimethyl)- Ptx and other vir-activated genes (vag genes),
including the filamentous hemagglutinin (FHA) locus (fha)
(5, 7), the pertactin gene (prn)
(21), fimbrial genes (fim-1, fim-2,
and fimX) (57), the adenylate cyclase gene
(cyaA) (24), a gene encoding a porin-like
protein (ompQ) (14), and a locus encoding serum
resistance (brkAB) (53, 56) have been shown to
be coordinately regulated at the level of transcription by a sensory
transduction system encoded by the bvgAS (vir)
locus (34) (2, 22, 50). Expression of the
vir regulon in B. pertussis is affected by
diverse environmental signals (31, 32, 35). The presence
of sulfate anion (SO42 In addition to the vag genes, there are a set of genes that
are regulated in the opposite manner from the vag genes.
These vir-repressed genes (vrg-6,
vrg-8, vrg-24, vrg-53, and
vrg-73) are expressed during the avirulent state (4,
22, 34). In several of these genes, the repression by
bvg appears to be a result of binding of a 34-kDa
vir-activated repressor to an intergenic sequence in the
vrg coding DNA, which decreases transcription (3). Additional vir-repressed genes have been
identified and characterized. Functional analysis of these two surface
proteins may help to elucidate the physiologic role in modulation of
B. pertussis (48).
Mutations in the genes responsible for the synthesis and secretion of
an active Ptx molecule can also affect the virulence of the organism
(53, 56). The genes encoding the Ptx subunits have been
cloned and sequenced (27), and the operons for the Ptx
secretory genes (ptl) have been characterized
(54). Mutations in the S1 subunit of Ptx affect secretion
because of destabilization of the molecule (9). Mutations
in the ptl gene (55) also decrease Ptx secretion.
Transcription of the Ptx gene can be regulated by several mechanisms.
Upon phosphorylation of BvgA, the transcription factor binds to
specific promoter sequences that activate or repress transcription
(40, 52). A kinetic study has indicated that fha and bvg are transcribed 10 min after signal
transduction, but the ptx and cya genes are not
transcribed until 2 to 4 h after induction (42, 43).
The activation of Ptx and cya correlated with
accumulation of high intracellular levels of BvgA (42). Transcription of ptx requires higher levels of
phosphorylated BvgA than that of fha (47).
Genetic and DNase I protection data support a model of Ptx
activation in which phosphorylated BvgA binds to a high-affinity BvgA
binding site (6, 28). Cooperative binding of BvgA dimers
between the binding site and the promoter allows BvgA to interact with
RNA polymerase (RNP) (5, 6). More recently, a Ptx
accessory factor has been described that is required for transcription
of the gene in Escherichia coli. In addition, B. pertussis mutants have been identified that overexpress the Isolation and construction of B. pertussis bvgs mutants
(22, 34, 35) that are more resistant to antigenic
modulation by exogenous SO42 Bacterial strains.
Wild-type B. pertussis strain
CS-87 was used in these studies. This strain originated in China and
was brought to the National Institute of Child Health and Human
Development at the National Institutes of Health. Strain 9797, a Tohama
I derivative, was procured from the American Type Culture Collection
(Manassas, Va.). Organisms were stored at Culture media.
The medium used to grow CS-87 was similar to
the defined medium described by Stainer and Scholte (46).
One liter of medium contained 10.7 g of monosodium glutamate,
0.24 g of L-proline, 2.5 g of NaCl, 0.5 g of
KH2PO4, 0.2 g of KCl,
0.1 g of MgCl2 · 6H2O, 1.82 g of Tris base, 0.01 g of
FeSO4 · H2O, 0.02 g
of CaCl2 · 2H2O,
0.04 g of L-cysteine monohydrochloride, 0.1 g of
glutathione (reduced), 0.02 g of L-ascorbic acid, and
0.004 g of niacin. The monosodium glutamate, proline, NaCl,
KH2PO4, KCl,
MgCl2 · 6H2O Tris base,
and CaCl2 · 2H2O were
prepared in a basal formulation (1×) and autoclaved. The remaining
medium supplement was prepared in a concentrated form (100×) and
filter sterilized. The final pH of the complete medim ranged from 7.2 to 7.5. For some experiments, a modified SS (MSS) medium was used. The
MSS medium was supplemented with the following amounts of amino acids
per liter: 0.40 g of L-arginine monohydrochloride,
0.10 g of L-asparagine, 0.04 g of L-aspartic acid, 0.1 g of L-cysteine
monohydrochloride, 0.03 g of L-histidine, 0.10 g
of L-isoleucine, 0.10 g of L-leucine,
0.08 g of L-lysine monohydrochloride, 0.03 g of
L-methionine, 0.03 g of L-phenylalanine,
0.06 g of L-serine, 0.04 g of
L-threonine, 0.01 g of L-tryptophan, and
0.04 g of L-valine. This amino acid supplement was
prepared in a concentrated form (100×) and filter sterilized.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.11.6823-6830.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Bordetella pertussis Autoregulates
Pertussis Toxin Production through the Metabolism of Cysteine
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) was
observed in early stage growth, followed by a rapid decrease as the
cells entered into logarithmic growth. This loss was later followed by
the accumulation of large quantities of SO42
into the media in late-stage fermentation. Release of
SO42
into the media by the cells signaled the
decoupling of cell growth and Ptx production. Under conditions that
limited cysteine, a fivefold increase in Ptx production was observed.
Addition of barium chloride (BaCl2) to the culture further
increased Ptx yield. Our results suggest that B.
pertussis is capable of autoregulating the activity of the
bvg regulon through its metabolism of cysteine. Reduction of the amount of cysteine in the media results in prolonged vir expression due to the absence of the negative
inhibitor SO42
. Therefore, the combined
presence and metabolism of cysteine may be an important mechanism in
the pathogenesis of B. pertussis.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-cyclodextrin to sequester free
fatty acids has significantly increased Ptx production (15, 16,
58). Outer membrane vesicles produced in Stainer-Scholte
cultures contain significant amounts of adenylate cyclase,
lipopolysaccharide, and Ptx (18). Dissociation of Ptx from
these vesicles may also improve yields.
) or
nicotinic acid (31, 32) or growth at low temperature (37) results in decreased expression of ptx and
other virulence genes. Naturally occurring BvgS mutants
(49), site-directed mutants (34), and
serum-resistant mutants (12) have been shown to be less
sensitive to these environmental signals.
subunit of RNA polymerase, which in turn down-regulates expression of
the Ptx promoter (8, 28).
and nicotinic acid have been helpful in studying ptx gene
regulation. Still, investigators have yet to decipher the mechanism for
the reduction in the concentration of Ptx per optical density unit ([Ptx]/OD) commonly observed in wild-type strains grown in shake flasks and fermentation containing standard and more complex media (15, 16). In this study, we show that B. pertussis autoregulates Ptx production through the metabolic
conversion of cysteine to SO42
and pyruvic acid. Our data suggest that B. pertussis uses
the bvgs sensory system in response to accumulation of both
internal and external metabolic
SO42
.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C or maintained on
Bordet-Gengou agar (BGA; Becton Dickinson, Sparks, Md.) in a humid
incubator at 37°C.
Growth conditions. Shake flasks were inoculated with frozen seeds and grown 20 to 24 h before addition to the bioreactors. Shake flask cultures were transferred to the bioreactor when ODs were >1.0 at 600 nm. The bacteria were grown in triple-baffled Erlenmeyer flasks in a New Brunswick Innnova model 4300 shaking incubator maintained at 36.5°C or in a New Brunswick 20-liter BioFlo 4500 (New Brunswick Scientific, Edison, N.J.) run in batch mode with a working volume of 12 liters maintained at 36.5°C. The reactor was connected to an AFS Biocommand version 2.61 (New Brunswick Scientific), which collected data for pH, agitation, dissolved oxygen, temperature, and airflow rate and which had additional pumps for antifoam and pH control. The fermentation was maintained at a temperature of 36.5°C, with an aeration rate of 4.0 liters/min (pH 7.2) and a dissolved oxygen level of 40% by cascading the agitation rate from 200 rpm to 1,000 rpm. The pH was controlled by addition of 50% phosphoric acid, and foaming was controlled by addition of antifoam C (J. T. Baker, Phillipsburg, N.J.) as needed. The fermentation contained 11 liters of defined medium and was inoculated with 1 liter of an actively growing seed culture when the OD of the culture was >1.0. All chemicals were reagent grade and were obtained from J. T. Baker, Spectrum, New Brunswick, N.J., or Sigma, St. Louis, Mo., unless otherwise noted.
Fermentation sampling.
Samples were taken from a sterile
port every 3 to 6 h. The OD of each sample was measured by using
the Shimadzu UV 1601 spectrophotometer (Shimadzu, Columbia, Md.). A
30-ml sample was centrifuged at 9,000 rpm for 10 min at room
temperature with an SA 600 rotor in a Sorvall centrifuge. The
supernatants from the 30-ml samples were filter sterilized with a
0.2-µm-pore-diameter Millex-GV filter (Millipore, Bedford, Mass.).
This supernatant was used for
SO42
, Ptx, amino acid, and
organic acid analyses. The cells were resuspended in 10 ml of distilled
water, disrupted by nitrogen cavitation with a nitrogen bomb (Fike
Metal Products, Blue Springs, Mo.), and centrifuged as before, and the
supernatant was analyzed for internal
SO42
concentration. A 5-ml
sample was treated with 500 µl of 10% sodium dodecyl sulfate (SDS)
and used for trichloroacetic acid precipitation of intracellular and
extracellular proteins. The pellets were stored at
20°C, and the
supernatant and the SDS-treated samples were stored at 2 to 8°C.
Culture purity was verified by gram staining and plating on BGA and
Trypticase soy agar (Becton-Dickinson).
Medium reconstitution experiments. Culture supernatant from a B. pertussis culture grown to stationary phase in SS medium was lyophilized and was reconstituted with growth medium lacking NaCl, KH2PO4, KCl, Tris base, CalCl2 · 2H2O, and 0.1 g of MgCl2 · 6H2O. A fraction of this reconstituted spent medium was then added to a second culture of B. pertussis and was compared to the original medium used for Ptx production. Another fraction of the spent medium from the original culture was filtered through a membrane with a molecular weight cutoff of 3,000 (3,000 MW). Both the retentate and flowthrough were lyophilized and reconstituted as before. These mixtures were added to individual B. pertussis cultures at 18 h, and then samples for Ptx production were obtained at 23 and 28 h. The Ptx production and growth of these cultures containing reconstituted medium were then compared to Ptx production and growth in SS medium.
Nitrogen cavitation of cells. Bacterial pellets from 30-ml culture supernatants were suspended in 10 ml of distilled water. The aqueous portion of the cells was isolated by first disrupting the cells with a nitrogen cavitation apparatus (Fike Metal Products) at a pressure of 1,500 lb/in2 and then removing cellular debris by centrifugation at 10,000 rpm in a Sorvall centrifuge with an SA 600 rotor.
Cross-streaking experiments. Initial vertical streaks of strain CS-87 were made on individual BGA plates (Becton-Dickinson) and incubated at 36.5°C for 48 h. Secondary horizontal streaks were made when the sterile loop passed back and forth across the vertical streak. The cross-streaked plate was then incubated for 48 h at 36.5°C. Colonies were visualized with a Leica model MZ6 stereomicroscope (Leica, Buffalo, N.Y.) at a ×100 magnification, and the image was captured with a Digital Imaging System model IS-1000 (Alpha Innotech Co., San Leandro, Calif.).
Quantitative Ptx ELISA. Microtiter plates (Nunc Maxi-sorp; Vangard International, Neptune, N.J.) were sensitized by adding 0.1 ml per well of fetuin (Sigma Chemical Co.) at 0.04 mg/ml in 0.1 M sodium carbonate (pH 9.6). The plates were incubated overnight at 4°C. The plates were blocked for 1 h at room temperature (RT) with 0.1% fetal bovine serum-phosphate-buffered saline (PBS; pH 7.5). The plates were washed, and samples diluted in PBS-Brij 35 plus 0.02% bovine serum albumin were added to the fetuin-coated plates and incubated for 1 h at RT. After incubation, plates were washed and reacted with a monoclonal antibody to Ptx (19, 20, 44) for 2 h at RT. The plates were washed and the secondary antibodies, alkaline phosphatase-conjugated goat anti-mouse immunoglobulin G (IgG) and IgM (Tago, Burlingame, Calif.) diluted 1:3,000 in PBS-Brij, were added to the plate and incubated for 2 h at RT. The plates were washed and developed with p-nitrophenyl phosphate (Sigma) in a solution containing 0.1 M diethanolamine, 1 mM MgCl2, 0.1 mM ZnCl2, and 0.02% azide (pH 9.8) and incubated for 1 h at RT before the A405 was read. Selective supernatants were assayed with a CHO cell assay (53) to confirm the toxin levels measured in the Ptx enzyme-linked immunosorbent assay (ELISA) (data not shown).
SO42
determination.
Extracellular
and intracellular SO42
analyses were performed with a reproducible and quantitative assay
(30). The barium chloride reagent was prepared by
dissolving 40 mg of BaCl2 and 67.2 mg of
NaHCO3 in 60 ml of distilled water. Fifty
milliliters of 2N acetic acid was added, and the volume was brought to
500 ml with absolute ethanol. For the working
BaCl2 reagent, 100 ml of this solution was
diluted with 200 ml of absolute ethanol. The rhodizonate reagent was
prepared by dissolving 100 mg of ascorbic acid in 20 ml of distilled
water. The final volume was adjusted to 100 ml with absolute ethanol.
per sample was determined
by linear regression analysis of a standard curve generated by
different concentrations of ammonium SO42
ranging from 2.5 µg/ml
to 30.0 µg/ml.
Amino acid analysis. The analysis and quantification of amino acids were made by reverse-phase high-pressure liquid chromatography (RP-HPLC) with an on-line pre-column derivitization, as provided for the AminoQuant column (Hewlett-Packard, Wilmington, Del.). Primary acids were derivatized by the ortho-phthalaldehyde (OPA) reagent, while secondary amino acids were derivatized by the FMOC (9-fluorenylmethoxy carbonyl) reagent. For the primary amino acids, the mobile phase consisted of sodium acetate-triethanolamine-tetrahydrofuran (pH 7.2) and was detected at 338 nm. Secondary amino acids were eluted with a sodium acetate-methanol-acetonitrile mobile phase (pH 7.2) and were detected at 262 nm. The quantification of each amino acid was performed by comparison of the amino acid standard curve at different concentrations.
Pyruvic acid analysis. Pyruvic acid was detected with a model HP-1050 HPLC (Hewlett-Packard) in conjunction with the HP ChemStation version 2.0 software and containing a Bio-Rad Aminex HPX-87H column (Bio-Rad Laboratories, Burlingame, Calif.) with a mobile phase of 4 mM H2SO4. The column was equilibrated at 35°C, and the isocratic flow rate was 0.6 ml/min. The detection was done at 215 nm. Pyruvate was assessed by spiking the organic acid standard with pyruvate at a concentration of 2.5 g/liter. Pyruvic acid was quantified with a pyruvic acid analysis kit (Sigma Chemical Co.).
Statistical analysis. The Ptx and sulfate concentrations of each sample were calculated by linear regression analysis of Ptx and ammonium sulfate standard curves with the Dynex Revelation 3. 2 statistical analysis package (Dynex, Chantilly, Va.). A Ptx standard curve was generated by using twofold dilutions of a Ptx internal standard from 1.5 µg/ml to 0.012 µg/ml. Culture supernatants were measured for Ptx by prediluting duplicate samples 1:10 and then adding twofold dilutions of the prediluted duplicates to the ELISA plate. The coefficient of variance of duplicate samples was <3% for each assay. The plate-to-plate variation standard was <10%, and the day-to-day variation of the standard was <10%.
The sulfate standard curve was generated by performing dilutions of ammonium sulfate (NH4)2SO4 in media from 35 µg/ml to 3 µg/ml. Undiluted culture supernatants and the concentrated intracellular component of the bacterium were measured in triplicate. The plate-to-plate coefficient of variance of the standard curve ranged from 3 to 12%, and the day-to-day coefficient of variance of the standard averaged <6%.| |
RESULTS |
|---|
|
|
|---|
Determination of the presence of an inhibitor in culture
supernatants.
Studies of B. pertussis fermentation were
initiated to assess the possibility of increasing Ptx productivity in
batch fermentation. The ODs and [Ptx]/OD for two 20-liter
fermentations with SS medium are shown in Fig.
1. ODs rise linearly to 32 h, while
the [Ptx]/OD ratio begins to level off between 22 and 28 h,
suggesting that Ptx production and/or secretion shuts down in the
middle of fermentation. Experiments were then designed to determine the
presence of an inhibitory component in the medium causing this
down-regulation (Fig. 2). In the initial
experiment, the spent medium from actively growing B. pertussis cultures at 24 h was lyophilized, reconstituted with the basic salts, and added to another actively growing culture at
18 h. This resulted in a decrease in Ptx production without any
effect on growth of the culture (data not shown). The spent culture
supernatant was then fractionated with a 3,000-MW-cutoff filter. The
retentate fraction (fraction containing components with MW of >3,000)
was added back to a B. pertussis culture in a shake flask at
18 h and then grown for an additional 10 h. This fraction
demonstrated no inhibition of Ptx production (Fig 2A) or cell growth
(Fig. 2B). However, when the <3,000-MW permeate (fraction containing
components with MW of <3,000) was added to a culture at 18 h and
then grown for an additional 10 h, Ptx production was inhibited
(Fig. 2A), but cell growth was unaffected (Fig. 2B). As a control,
cultures containing SS medium alone showed normal Ptx production and
growth (Fig. 2A and B).
|
|
Identification of an inhibitor of adenylate cyclase-hemolysin toxin
activity.
Since the adenylate cyclase-hemolysin (AC) toxin gene of
B. pertussis is regulated in a similar manner to the
ptx gene, a basic cross-streaking experiment was performed
to determine if inhibitors are produced when the bacterium is grown on
BGA plates. The bacterial colonies in areas closest to the initial
streak showed less hemolytic activity than the ones away from the
streak (Fig. 3). This suggested that a
soluble component is secreted from colonies present in the initial
streak and diffusing through the agar to inhibit adenylate
cyclase-hemolysin (cyaA) toxin production in the fresh
colonies generated by the cross-streaks.
|
Identification of amino acid, pyruvic acid, and sulfur-containing
metabolites in fermentation.
To identify the soluble factors amino
acid, pyruvic acid, and sulfur-containing metabolites, amino acid and
pyruvic acid analyses were performed with samples derived from a
culture of B. pertussis grown in SS medium. Amino acid
analysis of fermentation in SS medium shows that the concentrations of
arginine, cysteine, and methionine increase over time, with the
appearance of methionine and cysteine starting at 15 h. The amount
of cysteine (2.5 µg/ml) was smaller than the amounts of methionine
(150 µg/ml) and arginine (650 µg/ml) at 30 h (Fig.
4A). Amino acid and pyruvic acid analyses in fermentation showed that cysteine began to appear in the medium at
15 h (Fig. 4A) at the same time as the rapid accumulation of pyruvic acid (Fig. 4B) to a concentration of 40.0 µg/ml. Since SO42
is a known by-product of
the cysteine metabolic pathway and an inhibitor of Ptx production, the
medium was then analyzed for the presence of
SO42
. The appearance of
SO42
in the medium followed
the pattern of the appearance of pyruvic acid at similar time points
(Fig. 4B and 5). The concentration of
SO42
in the medium was also
similar to the concentration of pyruvic acid (Fig. 4B and 5).
|
|
Effects of adding reduced amounts of cysteine to the media on Ptx
production.
Fermentation of strain CS-87 was performed with MSS
media to establish a baseline of Ptx and
SO42
production. Ptx
production ranged from 2 to 4 µg/ml (Fig.
6A), and external
SO42
accumulation reached 15 µg/ml at 24 h (Fig. 7). Initial
fermentation conditions were designed to determine if certain amino
acids were required for growth of B. pertussis, particularly
cysteine and methionine, two potential sources of sulfur. In these
amino acid "rescue" experiments, cultures grown in shake flasks
were added to the bioreactor containing MSS medium lacking arginine,
methionine, and cysteine. When these cultures stopped dividing,
arginine, methionine, and cysteine were sequentially added to determine which amino acid was required to restore growth. Only the addition of
cysteine was capable of restoring growth. Addition of cysteine was
followed by the release of
SO42
in the medium (data not
shown).
|
|
Effects of adding the Ba2+ ion to the medium on Ptx
production.
Experiments were then designed that not only limited
cysteine in the medium, but also precipitated excess internal and
external SO42
with
BaCl2 (LCMSSBa). In LCMSSBa fermentation,
BaCl2 was added to the culture at 12 h to a
final concentration of 20 mM. Addition of BaCl2
did not significantly affect the final OD of B. pertussis strain CS-87 compared to that with MSS medium (Fig. 6B). The ODs in the
two LCMSSBa experiments were >4.0 after 36 h and >6.0 after 28 h (Fig. 6B), and the Ptx yields were greater than those
observed in LCMSSB or LCMSSFB experiments (Fig. 6A). The amounts
of Ptx produced in the two independent LCMSSBa experiments were
65 µg/ml after 32 h in experiment 1 and 80.8 µg/ml after
18 h in experiment 2.
Ptx production rates. The highest specific production rates of the B. pertussis cells grown in medium that limited cysteine were 14.6 µg/ml/OD (LCMSSB) at 23 h and 14.1 µg/ml/OD (LCMSSFB) at 26 h, respectively. By combining smaller amounts of cysteine with precipitation of sulfate from the cultures by using BaCl2, Ptx production rates increased to 17.2 µg/ml/OD at 19.2 h in experiment 1 and 35.8 µg/ml/OD at 20.2 h in experiment 2. In comparison, the highest specific productivity in MSS medium was 1.0 µg/ml/OD at 22 h. Ptx production in LCMSSBa cultures reached the highest levels sooner in fermentation than those in cultures grown in medium that limited cysteine alone. Similar results in Ptx production were obtained with ATCC strain 9797 with these media (data not shown).
Effect of SO42
accumulation and release
on Ptx production.
To determine if the decoupling of Ptx
production with growth rate was signaled by the metabolism of cysteine,
external SO42
levels were
measured during fermentation. The accumulation of SO42
in LCMSSB and LCMSSFB
cultures occurred later in fermentation than in MSS cultures and did
not reach >10 µg/ml until after 24 h (Fig. 7). This correlated
well with the time at which the Ptx production rate of the culture
reached its maximum. In cultures containing
BaCl2,
SO42
accumulation was observed
later in fermentation in experiment 1 and was largely undetectable in
experiment 2 (Fig. 7). These results suggest that the concentration of
BaCl2 in the medium was sufficient to sequester
most of the internal and external SO42
.
levels could be used to
predict Ptx production patterns. Intracellular SO42
levels of cells grown in
medium that limited cysteine were rapidly diluted by cell division in
early stages of fermentation (Fig. 7). The dissipation of internal
SO42
patterned the growth rate
of the culture (Fig. 6B and 7). In these cultures, the internal
SO42
levels dropped below 20 mM between 10 and 14 h in fermentation (Fig. 7). Cells that
eliminated internal SO42
more
rapidly (Fig. 7) appear to produce Ptx sooner in fermentation (Fig.
6A), which resulted in an increase in the total Ptx yield.
| |
DISCUSSION |
|---|
|
|
|---|
Immunization with an acellular pertussis vaccine formulated with detoxified Ptx has been shown to be a simple, safe, and effective way to prevent whooping cough in infants (17). Formation of the active toxin requires the assembly of five different subunits in the periplasm (36) and secretion through a highly selective gated channel in the outer membrane composed of at least nine Ptl proteins (55). In the absence of adequate secretion machinery and/or the presence of inactive toxin, Ptx accumulates in the cell (11, 53, 55). Therefore, the bacteria must properly assemble the toxin as well as produce the appropriate number of functional secretion machinery. Virulence factors are synthesized in response to environmental signals under the control of the bvg regulatory locus by transactivation of its own autoregulated promoter and the promoter of FHA followed by transactivation of cyaA and Ptx (42). Isolation of spontaneous mutations in BvgS that are less sensitive to environmental signals results in the constitutive synthesis of multiple bvg-regulated loci. (34). Other than the effects of environmental stimuli on the BvgAS regulatory activity, B. pertussis has not been shown to self-modulate virulent factor expression in response to growth conditions by altering its metabolic pathways.
Studies have shown that virulence factor expression is influenced by
temperature, pH, glutamate levels, free fatty acids, and environmental
compounds like nicotinic acid and
SO42
(15, 16, 23, 25,
26, 35, 37, 56). Addition of heptakis-(2,6-O-dimethyl)-
-cyclodextrin to the medium
increases Ptx yields significantly (15, 16, 58). However,
addition of this complex compound to the growth medium may pose adverse effects if it contaminates the formulated vaccine product. Our studies
have shown that the simple reduction in the cysteine in growth medium
enhanced Ptx production. Similar results were observed with ATCC strain
9797, a Tohama I derivative. This suggests that the bacterium responds
to the cysteine concentrations in its environment as well as
autoregulates virulence through recognition of exogenous and/or
endogenous SO42
.
Addition of BaCl2 to the medium enhanced Ptx
yields and appears to stabilize Ptx in the medium after cells enter the
stationary growth phase (Fig. 6A). This suggests that the
Ba2+ ion can compete for both intracellular and
extracellular SO42
in actively
growing cells to prevent recognition of
SO42
by the bvg
sensory system. This compound may also act to stabilize the toxin
and/or prevent it from reassociating with membrane blebs in the medium.
By modulating the concentration of cysteine and, in turn,
SO42
in the medium, we have
also observed an increase in the synthesis and secretion of other
virulence factors like FHA, CyaA, and pertactin (data not shown).
Additional experiments will focus on how various concentrations of
cysteine affect each of these other components. Moreover, the rate of
addition of cysteine may provide the cells with sufficient amounts of
cysteine for growth yet minimize the conversion to
SO42
and accumulation of
SO42
within the cell and
release into the medium.
Bacteria use a wide variety of metabolic enzymes to cause disease. B. pertussis cells have been able to coexist in the host environment due to their ability to adapt to the environment and evolve mechanisms to combat host defense mechanisms. These mechanisms allow B. pertussis to colonize and reproduce in the host and evade and disable the host defense system, as well as facilitate their transmission to a new host, propagating their infectious life cycle. B. pertussis has been shown to regulate its virulence genes by the ability to recognize diverse environmental signals. Based on our current understanding of the transmission and the etiology of whooping cough, there is very little knowledge of why this bacterium would turn its virulence factors on and off in the host. However, it is interesting to note that B. pertussis causes a severe infection in infants, whereas, most adult infections are less symptomatic. This might suggest the physiologic environment found in each might reflect differences in stimuli to the bacterium. Moreover, recent studies have shown that in vivo the Bvg states may not be the only important determinant for B. pertussis pathogenesis, suggesting an alternative mechanism for regulating virulence in the human host (29).
Investigators have postulated that the ionic composition of human blood
plasma may serve as a signal stimulus for the initiation of virulence,
since maximum expression of Ptx occurs at a sodium concentration at or
above 140 mM, the human physiological sodium concentration
(15). It has also been found that the concentration of
cysteine in plasma is 70 to 108 µmol/liter in adults compared to 10 to 40 µmol/liter in the infant (10). Our studies on the growth of B. pertussis in fermentation suggest that the
conversion of cysteine to SO42
may be an important mechanism used by the organism in regulating its
virulence and expressing its virulence factors. Therefore, the amount
and availability of cysteine in the physiological environment encountered by the organism may be one of the important factors in the
differences found in the clinical manifestations of this disease in
adult and infant populations.
The ability of B. pertussis to switch from
bvg-activated to bvg-repressed genes suggests
that the organism has evolved a quorum sensing mechanism(s) that
controls its virulence. Recent studies suggest that this may not be the
only mechanism, since the regulation of the bvg-repressed
genes is not required for B. pertussis disease in the mouse
aerosal challenge model, and regulation of the bvg-activated genes is not required for virulence (33). Examination and
analysis of the metabolic utilization of the nutrients required for
B. pertussis growth and virulence factor production suggest
that quorum sensing of the external environment may not be the only mechanism. B. pertussis seems to have evolved a mechanism
that may sense the internal metabolites in relationship to its growth phase as well. If there is a phase in which B. pertussis
modulates expression of the bvg-regulated genes inside the
host, it must occur late in infection at a time when the bacteria has
established a disease state. Our results suggest that this may occur as
the bacteria reach a certain cell density or growth state at which cysteine metabolism is highly active. The relationship between cysteine
and the production of pyruvic acid and
SO42
observed during different
growth phases suggests that the metabolism of cysteine may play an
important role in the virulence of the organism. Further examination of
the feedback mechanism utilized by the bacterium will require the
isolation and characterization of the enzymes involved in cysteine metabolism.
| |
ACKNOWLEDGMENTS |
|---|
We gratefully thank Susan Mindel, Kirk Bayones, John Salim, Wei Yuan, and Misha Donets of the Baxter Healthcare Corporation for technical assistance and Max Kristiansen for assistance with statistical analysis. We also gratefully thank Scott Stibitz (Center for Biologics Evaluation and Research, FDA, Bethesda, Md.), Mark S. Peppler and Trevor H. Stenson (University of Alberta, Edmonton, Canada), Jeffrey F. Miller (University of California, Los Angeles, Calif.), and Akshay Goel (Baxter Healthcare Corporation) for reagents, technical assistance, and scientific advice.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Baxter Healthcare Corporation, 10150 Old Columbia Rd., Columbia, MD 21046-2358. Phone: (410) 309-7147. Fax: (410) 381-3385. E-mail: John_Bogdan{at}Baxter.com.
Editor: D. L. Burns
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Andorn, N., J. B. Kaufman, T. R. Clem, R. Fass, and J. Shiloach. 1990. Large-scale growth of Bordetella pertussis for production of extracellular toxin. Ann. N. Y. Acad. Sci. 589:363-371[CrossRef][Medline]. |
| 2. |
Arico, B.,
J. F. Miller,
C. Roy,
S. Stibitz,
D. Monack,
S. Falkow,
R. Gross, and R. Rappuoli.
1989.
Sequences required for expression of Bordetella pertussis virulence factors share homology with prokaryotic signal transduction proteins.
Proc. Natl. Acad. Sci. USA
86:6671-6675 |
| 3. |
Beattie, D. T.,
M. J. Mahan, and J. J. Mekalanos.
1993.
Repressor binding to a regulatory site in the DNA coding sequence is sufficient to confer transcriptional regulation of the vir-repressed genes (vrg genes) in Bordetella pertussis.
J. Bacteriol.
175:519-527 |
| 4. |
Beattie, D. T.,
R. Shahin, and J. J. Mekalanos.
1992.
A vir-repressed gene of Bordetella pertussis is required for virulence.
Infect. Immun.
60:571-577 |
| 5. |
Boucher, P. E.,
K. Murakami,
A. Ishihama, and S. Stibitz.
1997.
Nature of DNA binding and RNA polymerase interaction of the Bordetella pertussis BvgA transcriptional activator at the fha promoter.
J. Bacteriol.
179:1755-1763 |
| 6. |
Boucher, P. E., and S. Stibitz.
1995.
Synergistic binding of RNA polymerase and BvgA phosphate to the pertussis toxin promoter of Bordetella pertussis.
J. Bacteriol.
177:6486-6491 |
| 7. |
Boucher, P. E.,
M.-S. Yang,
D. M. Schmidt, and S. Stibitz.
2001.
Genetic and biochemical analyses of BvgA interaction with the secondary binding region of the fha promoter of Bordetella pertussis.
J. Bacteriol.
183:536-544 |
| 8. |
Carbonetti, N. H.,
A. Romashko, and T. J. Irish.
2000.
Overexpression of the RNA polymerase alpha subunit reduces transcription of Bvg-activated virulence genes in Bordetella pertussis.
J. Bacteriol.
182:529-531 |
| 9. |
Craig-Mylius, K. A.,
T. H. Stenson, and A. A. Weiss.
2000.
Mutations in the S1 subunit of pertussis toxin that affect secretion.
Infect. Immun.
68:1276-1281 |
| 10. | Diem, K., and C. Lentner. 1970. Scientific tables. Documenta Geigy, 7th ed., no. 574. Ciba-Geigy, Ltd., Basel, Switzerland. |
| 11. |
Farizo, K. M.,
T. Huang, and D. L. Burns.
2000.
Importance of holotoxin assembly in Ptl-mediated secretion of pertussis toxin from Bordetella pertussis.
Infect. Immun.
68:4049-4054 |
| 12. | Fernandez, R. C., and A. A. Weiss. 1998. Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS Microbiol. Lett. 163:57-63[CrossRef][Medline]. |
| 13. |
Field, L. H., and C. D. Parker.
1979.
Effects of fatty acids on growth of Bordetella pertussis in defined medium.
J. Clin. Microbiol.
9:651-653 |
| 14. |
Finn, T. M., and D. F. Amsbaugh.
1998.
Vag8: a Bordetella pertussis bvg-regulated protein.
Infect. Immun.
66:3985-3989 |
| 15. | Frohlich, B. T., E. R. Bernardez Clark, G. R. Siber, and R. W. Swartz. 1995. Improved pertussis toxin production by Bordetella pertussis through adjusting the growth medium's ionic composition. J. Biotechnol. 39:205-219[CrossRef][Medline]. |
| 16. | Frohlich, B. T., M. d'Alarcao, R. S. Feldberg, M. L. Nicholson, G. R. Siber, and R. W. Swartz. 1996. Formation and cell-medium partitioning of autoinhibitory free fatty acids and cyclodextrin's effect in the cultivation of Bordetella pertussis. J. Biotechnol. 45:137-148[CrossRef][Medline]. |
| 17. | Heron, I., F. M. Chen, and J. Fusco. 1999. DTaP vaccines from North American vaccine (NAVA): composition and critical parameters. Biologicals 27:91-96[CrossRef][Medline]. |
| 18. | Hozbor, D., M. E. Rodriguez, J. Fernandez, A. Lagares, N. Guiso, and O. Yantorno. 1999. Release of outer membrane vesicles from Bordetella pertussis. Curr. Microbiol. 38:273-278[CrossRef][Medline]. |
| 19. | Ibsen, P., and I. Heron. 1990. Quantitation of pertussis toxin in an enzyme linked immunosorbent assay with improved specificity. Biologicals 18:123-126[CrossRef][Medline]. |
| 20. |
Ibsen, P. H.,
A. Holm,
J. W. Petersen,
C. E. Olsen, and I. Heron.
1993.
Identification of B-cell epitopes on the S4 subunit of pertussis toxin.
Infect. Immun.
61:2408-2418 |
| 21. |
Kinnear, S. M.,
P. E. Boucher,
S. Stibitz, and N. H. Carbonetti.
1999.
Analysis of BvgA activation of the pertactin gene promoter in Bordetella pertussis.
J. Bacteriol.
181:5234-5241 |
| 22. |
Knapp, S., and J. J. Mekalanos.
1988.
Two trans-acting regulatory genes (vir and mod) control antigenic modulation in Bordetella pertussis.
J. Bacteriol.
170:5059-5066 |
| 23. | Lacey, B. W. 1960. Antigenic modulation of Bordetella pertussis. J. Hyg. 58:57-93. |
| 24. | Laoide, B. M., and A. Ullmann. 1990. Virulence dependent and independent regulation of the Bordetella pertussis cya operon. EMBO J. 9:999-1005[Medline]. |
| 25. | Licari, P., G. R. Siber, and R. Swartz. 1991. Production of cell mass and pertussis toxin by Bordetella pertussis. J. Biotechnol. 20:117-129[CrossRef][Medline]. |
| 26. | Licari, P., L. Winberry, and R. Swartz. 1991. The effect of pH on the production of pertussis toxin by Bordetella pertussis. J. Biotechnol. 17:189-193[CrossRef][Medline]. |
| 27. | Locht, C. 1999. Molecular aspects of Bordetella pertussis pathogenesis. Int. Microbiol. 2:137-144[Medline]. |
| 28. | Marques, R. R., and N. H. Carbonetti. 1997. Genetic analysis of pertussis toxin promoter activation in Bordetella pertussis. Mol. Microbiol. 24:1215-1224[CrossRef][Medline]. |
| 29. |
Martinez de Tejada, G.,
P. A. Cotter,
U. Heininger,
A. Camilli,
B. J. Akerley,
J. J. Mekalanos, and J. F. Miller.
1998.
Neither the Bvg phase nor the vrg6 locus of Bordetella pertussis is required for respiratory infection in mice.
Infect. Immun.
66:2762-2768 |
| 30. | Melnicoff, M. J., J. J. Godleski, and J. P. Bercz. 1976. An automated method for the determination of sulfate. Res. Commun. Chem. Pathol. Pharmacol. 14:377-386[Medline]. |
| 31. |
Melton, A. R., and A. A. Weiss.
1989.
Environmental regulation of expression of virulence determinants in Bordetella pertussis.
J. Bacteriol.
171:6206-6212 |
| 32. |
Melton, A. R., and A. A. Weiss.
1993.
Characterization of environmental regulators of Bordetella pertussis.
Infect. Immun.
61:807-815 |
| 33. |
Merkel, T. J.,
S. Stibitz,
J. M. Keith,
M. Leef, and R. Shahin.
1998.
Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis.
Infect. Immun.
66:4367-4373 |
| 34. |
Miller, J. F.,
S. A. Johnson,
W. J. Black,
D. T. Beattie,
J. J. Mekalanos, and S. Falkow.
1992.
Constitutive sensory transduction mutations in the Bordetella pertussis bvgS gene.
J. Bacteriol.
174:970-979 |
| 35. |
Miller, J. F.,
J. J. Mekalanos, and S. Falkow.
1989.
Coordinate regulation and sensory transduction in the control of bacterial virulence.
Science
243:916-922 |
| 36. |
Pizza, M.,
A. Bartoloni,
A. Prugnola,
S. Silvestri, and R. Rappuoli.
1988.
Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity.
Proc. Natl. Acad. Sci. USA
85:7521-7525 |
| 37. | Prugnola, A., B. Arico, R. Manetti, R. Rappuoli, and V. Scarlato. 1995. Response of the bvg regulon of Bordetella pertussis to different temperatures and short-term temperature shifts. Microbiology 141:4-34. |
| 38. | Robinson, A., L. I. Irons, and L. A. Ashworth. 1985. Pertussis vaccine: present status and future prospects. Vaccine 3:11-22[CrossRef][Medline]. |
| 39. | Ross, E. M. 1985. Immunisation against diphtheria, tetanus, pertussis and polio 5. Practitioner 229:795-799[Medline]. |
| 40. |
Roy, C. R.,
J. F. Miller, and S. Falkow.
1989.
The bvgA gene of Bordetella pertussis encodes a transcriptional activator required for coordinate regulation of several virulence genes.
J. Bacteriol.
171:6338-6344 |
| 41. | Rutter, D. A., L. A. Ashworth, A. Day, S. Funnell, F. Lovell, and A. Robinson. 1988. Trial of a new acellular pertussis vaccine in healthy adult volunteers. Vaccine 6:29-32[CrossRef][Medline]. |
| 42. | Scarlato, V., B. Arico, A. Prugnola, and R. Rappuoli. 1991. Sequential activation and environmental regulation of virulence genes in Bordetella pertussis. EMBO J. 10:3971-3975[Medline]. |
| 43. | Scarlato, V., A. Prugnola, B. Arico, and R. Rappuoli. 1991. The bvg-dependent promoters show similar behaviour in different Bordetella species and share sequence homologies. Mol. Microbiol. 5:2493-2498[CrossRef][Medline]. |
| 44. | Schou, C., M. Au-Jensen, and I. Heron. 1987. The interaction between pertussis toxin and 10 monoclonal antibodies. Acta Pathol. Microbiol. Immunol. Scand. C 95:177-187[Medline]. |
| 45. |
Sekura, R. D.,
F. Fish,
C. R. Manclark,
B. Meade, and Y. L. Zhang.
1983.
Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase.
J. Biol. Chem.
258:14647-14651 |
| 46. |
Stainer, D. W., and M. J. Scholte.
1970.
A simple chemically defined medium for the production of phase I Bordetella pertussis.
J. Gen. Microbiol.
63:211-220 |
| 47. | Steffen, P., S. Goyard, and A. Ullmann. 1996. Phosphorylated BvgA is sufficient for transcriptional activation of virulence-regulated genes in Bordetella pertussis. EMBO J. 15:102-109[Medline]. |
| 48. | Stenson, T. H., and M. S. Peppler. 1995. Identification of two bvg-repressed surface proteins of Bordetella pertussis. Infect. Immun. 63:3780-3789[Abstract]. |
| 49. | Stibitz, S., W. Aaronson, D. Monack, and S. Falkow. 1989. Phase variation in Bordetella pertussis by frameshift mutation in a gene for a novel two-component system. Nature 338:266-269[CrossRef][Medline]. |
| 50. |
Stibitz, S., and M. S. Yang.
1991.
Subcellular localization and immunological detection of proteins encoded by the vir locus of Bordetella pertussis.
J. Bacteriol.
173:4288-4296 |
| 51. | Thalen, M., I. J. van den, W. Jiskoot, B. Zomer, P. Roholl, C. de Gooijer, C. Beuvery, and J. Tramper. 1999. Rational medium design for Bordetella pertussis: basic metabolism. J. Biotechnol. 75:147-159[CrossRef][Medline]. |
| 52. |
Uhl, M. A., and J. F. Miller.
1994.
Autophosphorylation and phosphotransfer in the Bordetella pertussis BvgAS signal transduction cascade.
Proc. Natl. Acad. Sci. USA
91:1163-1167 |
| 53. |
Weiss, A. A., and M. S. M. Goodwin.
1989.
Lethal infection by Bordetella pertussis mutants in the infant mouse model.
Infect. Immun.
57:3757-3764 |
| 54. | Weiss, A. A., E. L. Hewlett, G. A. Myers, and S. Falkow. 1985. Genetic studies of the molecular basis of whooping cough. Dev. Biol. Stand. 61:11-19[Medline]. |
| 55. |
Weiss, A. A.,
F. D. Johnson, and D. L. Burns.
1993.
Molecular characterization of an operon required for pertussis toxin secretion.
Proc. Natl. Acad. Sci. USA
90:2970-2974 |
| 56. |
Weiss, A. A.,
A. R. Melton,
K. E. Walker,
C. Andraos-Selim, and J. J. Meidl.
1989.
Use of the promoter fusion transposon Tn5 lac to identify mutations in Bordetella pertussis vir-regulated genes.
Infect. Immun.
57:2674-2682 |
| 57. | Willems, R., A. H. Paul, G. van der Heide, A. R. ter Avest, and F. R. Mooi. 1990. Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation. EMBO J. 9:2803-2809[Medline]. |
| 58. | Zealey, G. R., S. M. Loosmore, R. K. Yacoob, S. A. Cockle, L. K. Boux, L. D. Miller, and M. H. Klein. 1990. Gene replacement in Bordetella pertussis by transformation with linear DNA. Bio/Technology 8:1025-1029[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»